Pamufetinib mesylate NEW
| Price | $197 | $747 | $1240 |
| Package | 5mg | 50mg | 100mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Pamufetinib mesylate | CAS No.: 1688673-09-7 |
| Supply Ability: 10g | Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Pamufetinib mesylate |
| Description | Pamufetinib mesylate (TAS-115 mesylate) is a potent vascular endothelial growth factor receptor (VEGFR) antagonist and hepatocyte growth factor receptor (c-Met) inhibitor used in the study of cancer and respiratory diseases. |
| In vitro | Pamufetinib mesylate is an ATP antagonist with inhibition constants (Ki) of 12 nM and 39 nM for rVEGFR2 and rMET, respectively.It potently inhibits the kinase activity of VEGFR2 and MET and their signaling-dependent cellular growth, with effects comparable to other known VEGFR or MET inhibitors. In addition, Pamufetinib mesylate caused less damage to a variety of normal cells than other VEGFR inhibitors. At concentrations below 10 μM, Pamufetinib mesylate did not affect the growth of PC-9 or HCC827 cells, but was able to concentration-dependently reverse HGF-induced resistance in both cell lines when combined with erlotinib. In addition, Pamufetinib mesylate inhibits VEGF production and endothelial cell proliferation in cancer cells. [1][2] |
| In vivo | Pamufetinib mesylate (50 mg/kg/d) was able to completely inhibit tumor growth during treatment. And in a MET-amplified human cancer transplant model, Pamufetinib mesylate (200 mg/kg/d) regressed tumor volume by 48% from the initial volume. In this model, the 50% effective dose (ED50) of Pamufetinib was estimated to be 8 mg/kg/d. Pamufetinib mesylate significantly prolonged survival in mice when administered at doses of 50 or 200 mg/kg/d. Meanwhile, Pamufetinib mesylate effectively inhibited angiogenesis in the PC-9/HGF tumor model. In addition, the combination of erlotinib and Pamufetinib mesylate successfully inhibited PC-9/HGF tumor growth and delayed tumor regeneration that was still associated with persistent vasculature inhibition even after cessation of treatment. [1][2] |
| Storage | keep away from direct sunlight,store at low temperature,keep away from moisture | store at -20°C | Shipping with blue ice. |
| Solubility Information | DMSO : 60.00 mg/mL (97.61 mM), Sonication is recommended. |
| Keywords | TAS 115 Mesylate |
| Inhibitors Related | Ribociclib | Nintedanib | Regorafenib monohydrate | Sunitinib Malate | Sorafenib | Crizotinib | Regorafenib | Ponatinib | Sorafenib tosylate | Lenvatinib mesylate | Pazopanib | Axitinib |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $46.00/1mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
| $0.00/10g |
VIP6Y
|
Zison Pharmaceutical (Shandong) Co., Ltd.
|
2024-05-24 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY